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Abstract
It is unclear to what extent patients with pancreatic cancer have cachexia and had a 
dietetic consult for nutritional support. The aim was to assess the prevalence of ca-
chexia, dietitian consultation, and overall survival in these patients. This prospective 
multicenter cohort study included patients with pancreatic cancer, who participated in 
the Dutch Pancreatic Cancer Project and completed patient reported outcome measures 
(2015–2018). Additional data were obtained from the Netherlands Cancer Registry. 
Cachexia was defined as self-reported >5% body weight loss, or >2% in patients with a 
BMI <20 kg/m2 over the past half year. The Kaplan–Meier method was used to analyze 
overall survival. In total, 202 patients were included from 18 centers. Cachexia was 
present in 144 patients (71%) and 81 of those patients (56%) had dietetic consultation. 
Cachexia was present in 63% of 94 patients who underwent surgery, 77% of 70 patients 
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1 |  INTRODUCTION
Patients with pancreatic ductal adenocarcinoma and periampul-
lary carcinoma (hereafter, pancreatic cancer) frequently present 
with malnutrition.1 Weight loss or even cachexia is reported in up 
to 80% of patients with pancreatic cancer.2–4 Weight loss could 
be caused by reduced dietary intake due to anorexia, abdominal 
pain, nausea, diarrhea, catabolic effects of the tumor, exocrine, 
and endocrine pancreatic insufficiency, and duodenal obstruc-
tion.5,6 Cachexia is defined as weight loss greater than 5%, or 
weight loss greater than 2% in individuals with a low body mass 
index (BMI, <20 kg/m2) or low skeletal muscle mass (sarcope-
nia) during the past 6 months.7 Cachexia is nowadays regarded to 
as the ultimate form of disease-related malnutrition, whereby, se-
vere malnutrition is defined as a weight loss of 10% or more.8,9 In 
pancreatic cancer, severe weight loss is associated with reduced 
survival, progressive disease, reduced treatment tolerance, and a 
decrease in quality of life.2,7 In patients with resectable cancer, 
it was shown that preoperative weight loss was associated with 
a shorter survival.10 This emphasizes the need for early screen-
ing (the risk of) for malnutrition and to start nutritional inter-
ventions, preferably before start of anticancer treatment, such as 
surgery.8,11–16 Dietitians can create an individualized treatment 
plan based on patients’ specific needs, for example, in the context 
of exocrine and/or endocrine insufficiency or nutritional impact 
symptoms. Currently, it is unclear to what extent patients with 
pancreatic cancer in a real-world setting have cachexia and had a 
dietetic consult for nutritional assessment and support. Therefore, 
the aims were to assess the prevalence of cachexia, dietetic con-
sultation, and overall survival in these patients.
2 |  MATERIALS AND METHODS
2.1 | Study design
This prospective multicenter cohort study included pa-
tients with pancreatic cancer who participated in the Dutch 
Pancreatic Cancer Project (PACAP).17 PACAP was estab-
lished in 2013 and includes a collection of clinical and patient 
reported outcome measures (PROMs, questionnaires) data. 
Currently, 48 centers participate in this nationwide project 
(www.pacap.nl). The PROMs data included self-reported 
nutritional parameters and body weight. Patient, tumor, and 
treatment data were retrieved from the Netherlands Cancer 
Registry (NCR). The NCR is a population-based registry in 
which all patients with a newly diagnosed malignancy are 
identified by automatic notifications of the national patholog-
ical archive (PALGA) and the National Hospital Discharge 
Register. Data within the NCR were collected from medical 
records by trained NCR administrators. The data from the 
PROMs and NCR were linked as all patients provided writ-
ten informed consent for participation and linkage of data. 
This study was performed in accordance with the STROBE 
guidelines.18
2.2 | Study population
All patients with pancreatic and periampullary cancer 
who participated in the PACAP PROMs registry between 
January 2015 and February 2018 were included. Patients 
were excluded if the questionnaire was not completed 
at baseline or if data on weight loss were lacking in any 
questionnaire.
2.3 | Data collection
The NCR includes clinical data, specifically sex, age, World 
Health Organization (WHO) performance status, comorbidi-
ties, tumor location, tumor stage, and treatment details regard-
ing resection and chemotherapy. Tumor stage was classified 
according to TNM 7 for patients diagnosed in 2015–2016 
and TNM 8 if diagnosed in 2017–2018.19,20 Tumor stage was 
based on the pathological TNM stage. If patients received 
who received palliative chemotherapy and 82% of 38 patients who had best supportive 
care. Dietitian consultation was reported in 53%, 52%, and 71%, respectively. Median 
overall survival did not differ between patients with and without cachexia, but decreased 
in those with severe weight loss (12 months (IQR 7–20) vs. 16 months (IQR 8–31), 
p = 0.02), as compared to those with <10% weight loss during the past half year. Two-
thirds of patients with pancreatic cancer present with cachexia of which nearly half had 
no dietetic consultation. Survival was comparable in patients with and without cachexia, 
but decreased in patients with more severe weight loss.
K E Y W O R D S
cachexia, dietetic consultation, nutritional interventions, pancreatic cancer, weight loss
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neoadjuvant therapy or if pathological TNM stage was not 
available, clinical TNM stage was used. Patients were cat-
egorized into three groups based on treatment (a) patients 
who underwent surgery (pancreatoduodenectomy, other 
pancreatectomy, or irreversible electroporation or radiofre-
quency ablation) and regardless of receiving or completing 
(neo)adjuvant chemotherapy; (b) patients who started pallia-
tive chemotherapy (patients who started neoadjuvant chemo-
therapy but did not undergo surgery were also included) and; 
(c) patients who received best supportive care. PROMs were 
collected at baseline and at 3, 6, 9, 12, 18, and 24 months 
after baseline, and yearly thereafter, until death or dropout. 
Results from baseline, 3, and 9 months were used, because 
dietary intake measurements (by the Dutch Healthy Diet 
Food Frequency Questionnaire (DHD-FFQ)) were available 
at these time points. A questionnaire was considered a base-
line measurement if the first questionnaire was completed 
(best supportive care group) or if it was completed between 
the date of diagnosis and (a) date of surgery or (b) date of 
start of neoadjuvant or palliative chemotherapy or within 
1  week after start of chemotherapy (i.e. considering that 
this would not influence the results, because most questions 
were about a longer retrospective period). Survival data were 
obtained by linkage with the Municipal Personal Records 
Database which contains the vital status of all Dutch inhabit-
ants. Overall survival time was defined as the time between 
date of diagnosis and date of death or censoring (1 February 
2020).
2.4 | Nutritional status
The PROMs contained questions on the following domains 
with respect to nutritional status and interventions: height, 
current weight, weight loss, dietetic consultation (including 
both intramural and extramural health care), self-reported 
reduced food intake, appetite, use of oral nutritional supple-
ments or parenteral nutrition, and tube feeding. BMI (kg/m2) 
was calculated from reported weight and height. A dietetic 
consultation is designed in accordance the Dutch Guidelines 
on malnutrition.21 A consult starts with screening of and di-
agnosing malnutrition and, in case of malnutrition, an exten-
sive nutritional assessment will be performed. Based on these 
results, an appropriate and individualized treatment plan will 
be made. Cachexia was defined as >5% body weight loss, or 
>2% with a BMI of <20 kg/m2 according to the international 
consensus criteria of Fearon et al. (2011).7 Severe weight 
loss (≥10%) was calculated from the reported body weight 
and weight loss over the past half year before diagnosis in 
the PROMs. The DHD-FFQ was completed by patients who 
consumed food orally. This is a validated questionnaire based 
on national dietary guidelines including questions about por-
tion sizes of bread, dairy, meat, fish, vegetables and candy, 
and alcohol consumption.22,23 Based on previously described 
methods, a protein score was calculated from the results of 
the DHD-FFQ ranging from 0 to 10 and categorized into 
two categories: 0–9.9 or 10.22,24 A score <10 corresponds 
with a protein intake that provides room for improvement by 
increasing the consumption of protein sources that were in-
cluded in the DHD-FFQ for the general healthy population.23 
Patients with cancer have higher protein requirements than 
healthy persons, and therefore, a protein intake assessed as 
needed to be improved for a healthy person could be inter-
preted as needed for dietetic consultation and/or oral nutri-
tional supplements for cancer patients.
2.5 | Statistical analysis
Baseline characteristics and nutritional parameters were 
presented using descriptive statistics. Normally distributed 
continuous data were presented as means with standard de-
viations (SD). Non-normally distributed continuous data 
were presented as medians with interquartile ranges (IQR). 
Categorical data were presented as frequencies with per-
centages. Median overall survival was calculated using the 
Kaplan–Meier method in patients with and without cachexia, 
and with <10% and ≥10% weight loss at baseline. Overall sur-
vival was compared using the log-rank test. p-values <0.05 
were considered statistically significant. Analyses were per-
formed using SAS software (version 9.4, SAS institute).
3 |  RESULTS
In total, 308 patients with pancreatic cancer from 18 cent-
ers were included in the PACAP cohort between 2015 and 
2018 (Figure 1). Of these patients, 95 were excluded because 
the first questionnaire was not completed at baseline and 11 
because data about weight loss were lacking. Of the remain-
ing 202 patients, 94 (47%) were female and the median age 
was 68 years (IQR 62–73, Table 1). The majority of patients 
(n = 132, 65%) had a WHO performance status of 0 or 1. Of 
the 94 patients (47%) with surgery, 79 (84%) underwent a 
pancreatoduodenectomy and 57 (61%) received neoadjuvant 
and/or adjuvant chemotherapy. Neoadjuvant therapy had a 
median duration of 50 days (IQR 43–91). Seventy out of the 
202 patients (35%) received palliative chemotherapy, and 38 
patients (19%) received best supportive care.
3.1 | Nutritional status
At diagnosis, cachexia was present in 144 patients (71%). In 
81 of these cachectic patients (56%), dietetic consultation 
was reported at baseline, compared to 7 patients in the group 
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without cachexia (12%). At baseline, 40% of all included pa-
tients (n = 81) presented with ≥10% weight loss during the past 
6 months and 52 of these patients (64%) had dietetic consulta-
tion. The protein score (<10) was insufficient in 147 patients 
(78%), of whom 58 patients (39%) were seen by a dietician.
Of all 94 patients who underwent surgery, 59 patients 
(63%) had cachexia at baseline of whom 31 (53%) had a 
dietetic consultation (Table 2, Figure 2). The presence of 
cachexia did not differ between patients with a BMI <25 
compared to those with a BMI ≥25 (35 patients (69%) vs. 
29 patients (69%), respectively, p = 0.965), as accounted for 
weight loss ≥10% (17 patients (33%) vs. 11 patients (26%), 
respectively, p = 0.455). At baseline, 4 patients (4%) received 
tube feeding, 28 patients (30%) used oral nutritional supple-
ments, and none used parenteral nutrition. The protein score 
was insufficient at baseline in 62 patients (66%), 23 of these 
patients (37%) had dietetic consultation, and 21 patients 
(34%) received oral nutritional supplements. Pancreatic en-
zyme supplementation was given to 13 patients (19%) at 
baseline and to 44 patients (64%) after surgery.
Of all 70 patients who received palliative chemotherapy, 
54 patients (77%) had cachexia at baseline (Table 3, Figure 
2). Dietitian consultation was offered in 28 of these cachectic 
patients (52%). In patients with a BMI ≥25, both cachexia (33 
patients (80%) vs. 21 patients (72%), respectively, p = 0.428) 
and weight loss ≥10% (21 patients (51%) vs. 10 patients 
(34%), respectively, p = 0.164) were not different compared 
to patients with a BMI <25. Of all 53 patients (76%) with an 
insufficient protein score at baseline, 17 (32%) had a dietetic 
consultation and 17 (32%) received oral nutritional supple-
ments. Pancreatic enzymes were supplemented in 12 patients 
(23%) at baseline and this increased to 17 patients (32%) after 
3 months.
Of all 38 patients with best supportive care 31 patients 
(82%) had cachexia of whom 22 had a dietetic consultation 
(71%) (Figure 2). Tube feeding and oral nutritional supple-
ments were used in 5 patients (13%) and 16 patients (42%), 
respectively. None used parenteral nutrition.
3.2 | Survival
Median overall survival in patients with cachexia was 
13  months (IQR 11–16), which was not significantly 
F I G U R E  1  Flow diagram of patient inclusion
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different to patients without cachexia (17 months, IQR 11–23, 
p = 0.18, Figure 3A), although patients with cachexia tended 
to have a poorer survival. In patients with ≥10% weight loss 
median overall survival was significantly lower, as compared 
to those with <10% weight loss (12 months (IQR 7–20) vs. 
16 months (IQR 8–31), p = 0.02, Figure 3B). Analyses in the 
subgroups based on treatment showed no differences in sur-
vival in patients with and without cachexia, and with <10% 
or ≥10% weight loss.
4 |  DISCUSSION
This prospective multicenter cohort study showed that 71% of 
patients with pancreatic cancer presented with cachexia at diag-
nosis of whom almost half had no dietetic consultation. Survival 
did not differ in patients with and without cachexia at diagnosis, 
but was shorter in patients with more severe weight loss (≥10%).
This is the first multicenter study to investigate the re-
al-life situation regarding cachexia and dietetic consultation 









Female, No. (%) 94 (47%) 42 (45%) 35 (50%) 17 (45%)
Age, years, median (IQR) 68 (62–73) 70 (62–74) 65 (60–70) 72 (62–77)
<55 17 (8%) 8 (9%) 6 (9%) 3 (8%)
55–64 60 (30%) 25 (27%) 25 (36%) 10 (26%)
65–74 83 (41%) 40 (43%) 33 (47%) 10 (26%)
≥75 42 (21%) 21 (22%) 6 (9%) 15 (39%)
Performance status, No. (%)
0 or 1 132 (65%) 60 (64%) 52 (74%) 20 (53%)
≥ 2 21 (10%) 4 (4%) 7 (10%) 10 (26%)
Missing 49 (24%) 30 (32%) 11 (16%) 8 (21%)
Comorbidities, No. (%)
0 45 (22%) 19 (20%) 17 (24%) 9 (24%)
1 66 (33%) 35 (37%) 22 (31%) 9 (24%)
≥2 70 (35%) 30 (32%) 24 (34%) 16 (42%)
Missing 21 (10%) 10 (11%) 7 (10%) 4 (11%)
Tumor location, No. (%)
Pancreas 163 (81%) 63 (67%) 64 (91%) 36 (95%)
Periampullary 39 (19%) 31 (33%) 6 (9%) 2 (5%)
Clinical stage, No. (%)
I 27 (13%) 14 (15%) 6 (9%) 7 (18%)
II 46 (23%) 32 (34%) 11 (16%) 3 (8%)
III 72 (36%) 43 (46%) 19 (27%) 10 (26%)
IV 55 (27%) 3 (3%) 34 (49%) 18 (47%)
Missing 2 (1%) 2 (2%) 0 (0%) 0 (0%)
Surgery, No. (%)
Pancreatoduodenectomy 79 (39%) 79 (84%) NA NA
Other pancreatectomy 11 (5%) 11 (12%) NA NA
IRE/RFA 4 (2%) 4 (4%) NA NA
Chemotherapy, No. (%)
Neoadjuvant only 5 (2%) 5 (5%) NA NA
Adjuvant only 42 (21%) 42 (45%) NA NA
Neoadjuvant and adjuvant 10 (5%) 10 (11%) NA NA
Palliative 70 (35%) NA 70 (100%) NA
Abbreviations: BMI, body mass index, IQR, interquartile range; IRE, irreversible electroporation; NA, not applicable; RFA, radiofrequency ablation.
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in pancreatic cancer. In previous studies, cachexia was di-
agnosed in 31%–41% of patients with resectable pancreatic 
cancer, which is lower than in our study.4,10 This could be 
explained by different definitions. In our study, BMI was also 
taken into account, whereas in previous studies cachexia was 
defined as weight loss >10%.4,7,10 We therefore also assessed 
weight loss ≥10%, which was 40% and thus, in line with pre-
vious studies. The high prevalence of cachexia underscores 
that physicians should be aware of cachexia in patients with 
pancreatic cancer.
In the three subgroups based on treatment for pancre-
atic cancer, patients undergoing best supportive care most 
often received dietitian support. In general, these patients 
were in their end-of-life, and therefore, the rate of dietetic 
consultation was higher than expected on forehand, while 
the low percentage of dietetic consultation in patients who 
underwent surgery is surprising. It could be speculated that 
this difference occurred because dietitian consultation is one 
of the few things that can be offered to patients with best 
supportive care. In addition, it should be noted that patients 
with best supportive care group are a selection of a relatively 
fit subgroup, since in general patients with a relatively good 
performance status are included in PACAP PROMs. It is pos-
sible that in these relatively fit patients, physicians may be 
more likely to start an intervention, including dietetic consul-





Patients who completed a 
questionnaire at baseline and 
after surgeryb (n = 69)
Baseline Baseline After 3 months
Dietitian consultation, No. (%) 36 (38%) 24 (35%) 40 (58%)
Missing 1 (1%) 1 (1%) 1 (1%)
Oral tube feeding, No. (%) 4 (4%) 4 (6%) 2 (3%)
Missing 1 (1%) 0 (0%) 2 (3%)
Oral nutritional supplements, 
No. (%)
28 (30%) 18 (26%) 26 (38%)
Reduced food intake, No. (%) 50 (53%) 35 (51%) 49 (71%)
Missing 1 (1%) 1 (1%) 0 (0%)
Self-reported BMI, kg/m2, 
median (IQR)
25 (22, 27) 25 (21, 28) 23 (21, 27)
<18.5 (underweight) 6 (6%) 5 (7%) 8 (12%)
18.5–25 (normal weight) 45 (48%) 32 (46%) 35 (51%)
≥25 (overweight) 42 (45%) 31 (45%) 26 (38%)
Missing 1 (1%) 1 (1%) 0 (0.0%)





Cachexia, No. (%) 59 (63%) 41 (59%) NA
Pancreatic enzyme 
supplementation, No. (%)
19 (20%) 13 (19%) 44 (64%)
Missing 2 (2%) 1 (1%) 5 (7%)
Protein score, No. (%)
<10 62 (66%) 44 (64%) 47 (68%)
10 26 (28%) 20 (29%) 17 (25%)
Missing (did not complete 
DHD-FFQ)
6 (6%) 5 (7%) 5 (7%)
Abbreviations: BMI, body mass index; NA, not applicable.
aBaseline is before or within one week after start neoadjuvant chemotherapy. 
bAfter surgery is based on the 3 or 9 month questionnaire, depending on time of surgery. 
cReported half year weight loss in baseline questionnaire. 
T A B L E  2  Nutritional and weight 
parameters in patients who underwent 
surgery
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dietitian support is not focusing on improving nutritional sta-
tus anymore, but is tailored to the patients’ needs and wishes 
enhancing comfort and support quality of life.26 In contrast, 
in patients with anticancer treatment, dietitian support may 
be considered less important by physicians compared to the 
impact of surgery or chemotherapy on survival. Another ex-
planation could be under reportation by the patient, or nu-
tritional support given by an experienced nurse practitioner. 
Dietitian counseling, however, could support the effects of 
anticancer treatments and might diminish complications by 
optimizing nutritional status.14,27 To optimize dietetic con-
sultation, all patients with pancreatic cancer planned for life 
enhancing treatment should be screened for malnutrition.28 
Screening could be performed according to the GLIM crite-
ria, which present a consensus scheme for diagnosing malnu-
trition in adults in clinical settings.8 Based on our results, it 
could be advised to include the screening for malnutrition in 
standard operating procedures, because the referral rate could 
be greatly improved.
It was expected that cachexia would negatively affect 
overall survival, but patients with and without cachexia 
at baseline did not show differences in overall survival. 
Nevertheless, patients with more severe weight loss (≥10%) 
had a decreased survival compared to those with <10% 
weight loss. This is also shown in previous studies.29,30 A 
higher percentage of weight loss, especially in combination 
with a lower BMI, independently decreases survival.30 This 
could partially explain the difference in results between ca-
chexia and severe weight loss. Moreover, the study might 
be underpowered for demonstrating a significant effect in 
patients with cachexia, because both in patients with ca-
chexia as well as in those with severe weight loss, survival 
is decreased by 4  months. It could be suggested that an 
early start of nutritional interventions in patients with ca-
chexia could prevent the development of severe weight loss 
and consequently improve survival. It should be mentioned 
that survival is also affected by other factors, such as tumor 
location, tumor stage, postoperative complications, use 
of (adjuvant) chemotherapy, and disease recurrence.31,32 
Prevention of weight loss only will probably not result in a 
clinically relevant improvement of survival.
In more than half of patients who underwent surgery and 
who received palliative chemotherapy, the protein score was 
<10. This already indicates that protein intake should be im-
proved because the score for protein intake has been based on 
cut-offs for the general healthy population. Since this study is 
focusing on pancreatic cancer patients, in whom it is even rec-
ommended to use a high protein diet, all patients with a score 
<10 should have a dietetic consultation.28 In our cohort, 39% 
of the patients with a protein score <10 had a dietetic con-
sultation and around one-third used oral nutritional supple-
ments. This demonstrates that there is room for improvement. 
After referral, a dietitian will devise a patient tailored nutri-
tional support plan based on the patient's nutritional intake to 
F I G U R E  2  Nutritional parameters in patients with cachexia at baseline. Percentages within the bars reflect the proportion of cachectic 
patients that had a dietitian consultation, received a nutritional intervention, or had a protein score <10
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improve nutritional status in patients undergoing surgery or 
palliative chemotherapy. In patients receiving best supportive 
care, dietary support should be focused at comfort and in-
creasing quality of life and should not be based on improving 
protein intake.
Another important aspect of malnutrition is exocrine 
pancreatic insufficiency.33–36 In patients with pancreatic 
cancer, exocrine insufficiency is highly prevalent, but cur-
rently underdiagnosed and undertreated.33,34,37 Enzyme sup-
plementation was not reported in more than a quarter of the 
patients that received palliative chemotherapy, which is low 
compared to the prevalence of exocrine insufficiency at di-
agnosis (66%).34 Nearly two-thirds of patients who under-
went surgery, however, received enzyme supplementation 
after surgery, probably because it was included in hospitals’ 
postoperative protocols.11 This could also be increased as 
the incidence of exocrine insufficiency in these patients is 
74% at 6 months postoperatively.33 Enzyme supplementation 
requires more attention and also support from a dietitian or 
nurse practitioner to provide patient education on proper use 
of enzymes.37,38
The strength of this prospective multicenter study is the 
real-life overview of the proportion of patients with cachexia 
and the current situation regarding dietetic consultation. The 
study also had some limitations. First, selection bias may be 
present toward a relatively high proportion of patients who 
underwent resection and/or received adjuvant or palliative 
chemotherapy.31 Possibly, fitter patients were more keen on 
being included, which might have led to an underestimation 
of malnutrition in our cohort. This emphasizes the need for 
proper identification and treatment of malnutrition even more. 
Second, nutritional support based on dietetic consultation 
Patients who completed 
the questionnaire at 
baselinea (n = 70)
Patients who completed 





Dietitian consultation, No. (%) 29 (41%) 21 (40%) 21 (40%)
 Missing 0 (0%) 0 (0%) 0 (0%)
Oral tube feeding, No. (%) 3 (4%) 2 (4%) 2 (4%)
Oral nutritional supplements, No. 
(%)
22 (31%) 15 (28%) 22 (42%)
Reduced food intake, No. (%) 55 (79%) 42 (79%) 33 (62%)
Self-reported BMI, kg/m2, median 
(IQR)
25 (22, 26) 24 (22, 26) 23 (21, 25)
<18.5 (underweight) 1 (1%) 1 (2%) 3 (6%)
18.5–25 (normal weight) 40 (57%) 32 (60%) 36 (68%)
≥25 (overweight) 29 (41%) 20 (38%) 12 (23%)
 Missing 0 (0%) 0 (0%) 2 (4%)
Weight loss at baselineb , No. (%) N/A N/A
<10% 39 (56%)
≥10% 31 (44%)
Cachexia, No. (%) 54 (77%) N/A
Pancreatic enzyme 
supplementation, No. (%)
16 (23%) 12 (23%) 17 (32%)
 Missing 4 (6%) 4 (8%) 5 (9%)
Protein score, No. (%)
<10 53 (76%) 40 (75%) 37 (70%)
10 13 (19%) 10 (19%) 12 (23%)
Missing (did not complete 
DHD-FFQ)
4 (6%) 3 (6%) 4 (8%)
Abbreviations: BMI, body mass index; N/A, not applicable.
aBaseline is in patients who received palliative chemotherapy: before or within one week after start palliative 
chemotherapy. 
bReported half year weight loss in baseline questionnaire. 
T A B L E  3  Nutritional and weight 
parameters in patients who received 
palliative chemotherapy
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could be underestimated, because of an under reportation of 
patients or support by a nurse practitioner. In large and spe-
cialized pancreatic surgery centers, an important role is often 
reserved for nurse practitioner or physician assistants expe-
rienced within pancreatic cancer to consult patients on their 
nutritional status and pancreatic enzyme supplementation. 
Third, the DHD-FFQ was included in the PROMs to assess 
the diet quality according (and derived protein score) to the 
national dietary guideline, but was only a qualitative measure 
and not quantitative. Fourth, patients, especially those who 
underwent surgery, frequently did not complete the baseline 
questionnaire before start of treatment which unfortunately 
resulted in exclusion of these patients and might be prevented 
by improved logistics within PACAP. Fifth, the criterion for 
cachexia that included the presence of sarcopenia was not 
used, because these data were not available in the NCR or 
PROMs.7 The loss of skeletal muscle mass depletion is the 
main aspect of malnutrition that predicts the risk of physical 
impairment, complications and mortality, and probably led to 
an underestimation of patients with cachexia.28,39,40 However, 
some advocate to focus on cachexia rather than sarcopenia in 
pancreatic cancer, because cachexia is the main problem.41
In conclusion, this study showed that over two-thirds 
of patients with pancreatic cancer present with cachexia of 
which nearly half had no dietetic consultation. Only 39% of 
patients with a protein score <10 had a dietetic consultation 
and pancreatic enzyme supplementation could be increased. 
Survival was comparable in patients with and without ca-
chexia, but significantly decreased in patients with severe 
weight loss (≥10%) suggesting the importance of prevent-
ing further weight loss. Increased awareness of cachexia and 
severe weight loss, screening on (the risk) of malnutrition 
based on the GLIM criteria, and dietetic consultation to im-
prove protein intake could be helpful improving treatment 
outcomes.
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